Business
Archived — This article has been archived. The information may be outdated.
Dr Reddy's to distribute Qdenga for ages 4-60
The Hindu BusinessLine··18 Sept
Takeda will bring dengue vaccine Qdenga to India through an exclusive distribution deal with Dr Reddy's Laboratories. Private-market supply is expected in the first half of 2027, the companies said. CDSCO approved Qdenga in July 2026 for people aged 4-60 years. It is given as two doses three months apart for pediatric and adult use.
Prism
What It Means For You
- Eligible people will access Qdenga through private channels first, not the public immunisation programme.
- No pre-vaccination dengue screening is required for the two-dose schedule, Business Standard reported.
- Public-programme inclusion remains a longer-term ambition, Takeda said.
What's Happening
- Takeda Biopharmaceuticals India and Dr Reddy's formalised exclusive private-market promotion and distribution rights.
- Qdenga (TAK-003) is a live-attenuated tetravalent vaccine covering all four dengue serotypes, the company said.
- Global trials enrolled more than 60,000 participants across eight dengue-endemic countries.
What Approval Covers in India
- CDSCO cleared the vaccine in July 2026 for ages 4 to 60.
- WHO reported 14.4 million dengue cases and 11,201 deaths globally in 2024, including 232,425 cases and 233 deaths in India.
- Mahender Nayak of Takeda welcomed a Parliamentary Committee suggestion to consider dengue vaccine for UIP.
all-news
